Comprehensive Cancer Panels include 153 genes that may contribute to hereditary cancer risk. These panels consist of established genes associated with cancer as well as newly identified candidate genes with potential cancer associations, although at uncertain or diminished risk. In families and individuals who are dealing with intricate conditions, more comprehensive testing might be beneficial. Using our Comprehensive Cancer Panels, we can detect disease-causing variations and assess potential cancer susceptibilities from supplementary candidate genes.

In the Complete Comprehensive Cancer Panel, 153 genes associated with hereditary cancer are evaluated. These genes include established cancer risk genes, as well as candidate genes that may have recently been discovered. As a result, the panel increases the likelihood of detecting cancer susceptibility variants while examining candidate genes in-depth to provide both immediate and potential future insights.

Is this test right for me?

A hereditary cancer syndrome may be of benefit to adults exhibiting personal or familial indicators. Cancer onset before the age of 50, multiple primary cancers in one individual, and multiple affected individuals within a family may indicate a hereditary cancer predisposition. For certain pediatric patients, this testing may also be appropriate following a clinical and familial history assessment. It is possible to specify which genes should be excluded on the test requisition form. This test is designed to identify individuals with a hereditary pathogenic variant in their germline and is not validated for detecting mosaicism below a 20% threshold. It cannot be ordered on tumor tissue.

In what ways can it benefit a patient?

Patients with hereditary cancer susceptibility benefit from heightened surveillance and preventive measures to effectively mitigate their cancer risk. Insights gained through candidate gene testing can prove invaluable in shaping future clinical approaches. Identifying the gene implicated can inform medical management and prevent unnecessary follow-ups. Moreover, testing the patient's family members can help determine their risk profile. If the patient has a pathogenic variant, close relatives (such as children, siblings, and parents) may be at heightened risk. In some circumstances, childhood screening may be necessary.